Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Cell line misidentification and cross-contamination are well-documented risks in biomedical research and biomanufacturing. According to the International Cell Line Authentication Committee (ICLAC), an estimated 15-20% of cell lines in use today are misidentified or cross-contaminated. For GMP cell banks intended for clinical use, misidentification can lead to product failure, regulatory rejection, or patient safety risks.
Creative Biogene provides complete cell line authentication services aligned with ICH Q5D Section 4.2, including STR profiling (human cells), species confirmation (COI barcoding/isoenzyme analysis), and cross-contamination screening. All testing is performed under GMP-aligned conditions, with full validation packages and IND/BLA-ready test reports to support your regulatory submissions.
| Method | Principle | Resolution Level | Best For |
| STR profiling | PCR + capillary electrophoresis of 8-16 STR loci + Amelogenin | Individual (human); sub-species (CHO) | Human cell line authentication (MCB/WCB) |
| Isoenzyme analysis | Electrophoretic separation of LDH, MDH, and G6PD | Species level | Non-human cell line species screening |
| COI sequencing | Sanger sequencing of ~650 bp COI gene | Species level (distinguishes close species) | Species confirmation for all mammals |
Resolution increases from isoenzyme analysis to COI sequencing to STR profiling.
All authentication methods at Creative Biogene are internally validated: STR primer specificity, isoenzyme reference pattern coverage, and COI sequencing analysis pipelines. We provide complete validation documents and test reports to support IND/BLA submissions for cell substrate characterization.
Per ICH Q5D Section 4.2, cell bank characterization must include identity testing to confirm that the MCB and WCB are identical to the original cell line and free from cross-contamination.
Need a custom authentication plan for your cell bank? Our technical team will provide a tailored strategy based on your cell type, passage history, and regulatory stage.
Q: How do I authenticate CHO cells?
A: CHO cells lack a standard STR database. Recommended strategy: (1) species confirmation by COI sequencing or isoenzyme analysis; (2) identity consistency using CHO-specific STR markers (e.g., CHO-A05, CHO-B03) – establish an in-house reference profile; (3) optional karyotyping. Creative Biogene provides a complete CHO authentication package.
Q: How many STR loci should be tested?
A: ATCC recommends at least 8 autosomal STR loci + Amelogenin. Creative Biogene uses a 16-locus panel (D5S818, D13S317, D7S820, D16S539, vWA, TH01, TPOX, CSF1PO, D3S1358, D8S1179, D21S11, D18S51, D2S1338, D19S433, FGA, Amelogenin), ensuring comparability with global cell banks.
Q: How do I interpret extra allele peaks (possible contamination)?
A: Extra peaks >20% of the main peak height at multiple loci suggest cross-contamination (≥5% contaminating cells). If ≥80% of core loci match but extra alleles appear, low-level contamination is likely – re-banking from a clean source is recommended.
Q: What is the advantage of COI sequencing over isoenzyme analysis?
A: COI sequencing has higher resolution – it distinguishes closely related species (e.g., mouse vs. rat, CHO vs. CHOK1) and provides sequence data traceable to public databases (GenBank, BOLD). Isoenzyme analysis is low-cost and suitable for routine screening. For critical batches or ambiguous species, COI sequencing is recommended.
Q: How often should STR testing be performed during passaging?
A: Per ICH Q5B, test at MCB, WCB, and EOPC (end-of-production cells). Intermediate passages generally do not require testing unless abnormal morphology or growth is observed.
Copyright © 2026 Creative Biogene. All rights reserved.